FBXL19-AS1

Across TCGA pan-cancer cohorts, FBXL19-AS1 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated FBXL19-AS1 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher FBXL19-AS1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated FBXL19-AS1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCS show a favorable association.

LIHC, HNSC, and KIRC are the cancer types where FBXL19-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.437	0.609	<.001	59	view →
HNSC	OS	Tertile	All	0.759	0.588	.002	50	view →
KIRC	OS	Median	All	0.550	0.692	.002	45	view →
COAD	DFS	Median	All	0.373	0.618	<.001	42	view →
UCS	DFS	Tertile	IV	0.855	0.250	.024	38	view →
LUAD	DFS	Median	IV	0.381	0.817	.002	28	view →
LGG	OS	Median	All	0.754	0.864	<.001	28	view →
CESC	DFS	Quartile	III,IV	0.321	0.779	.025	22	view →
BLCA	DFS	Quartile	All	0.194	0.527	.012	22	view →
SKCM	OS	Median	IV	0.867	0.225	.001	21	view →
MESO	DFS	Quartile	IV	0.259	0.623	.006	15	view →
KIRP	DFS	Quartile	All	0.777	0.922	.011	14	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

FBXL19-AS1–LIHC (DFS)

Open the LIHC breakdown →